Ole Færgeman
Impact in
-
- Diabetes, Cardiovascular Risks, and Lipoproteins
-
- Blood Pressure and Hypertension Studies
- Cardiac Health and Mental Health
- Antiplatelet Therapy and Cardiovascular Diseases
Papers in
- Surgery 108
- Lipoproteins and Cardiovascular Health 102
-
- Diabetes, Cardiovascular Risks, and Lipoproteins 23
- Co-authors
- Kalevi Pyörälà (12 shared papers)ANDERS G. OLSSON (23 shared papers)JOHN K. KJEKSHUS (8 shared papers)Lars Wilhelmsen (5 shared papers)Katherine Margaret Berg (1 shared paper)Christian M. Spaulding (1 shared paper)Jim Slattery (1 shared paper)Michael Gnant (1 shared paper)
- Journals
- Atherosclerosis (16 papers)Clinical Genetics (12 papers)The American Journal of Cardiology (9 papers)Human Mutation (8 papers)Circulation (7 papers)
- Partner nations
- DenmarkUnited StatesUnited Kingdom
In The Last Decade
Ole Færgeman
197 papers receiving 19.4k citations
Ole Færgeman's Hit Papers
Peers
Comparison fields: 5 of 165
- Endocrinology, Diabetes and Metabolism 5.3k
- Cardiology and Cardiovascular Medicine 5.0k
- Surgery 9.7k
- Cancer Research 2.0k
- Family Practice 137
Countries citing papers authored by Ole Færgeman
This map shows the geographic impact of Ole Færgeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ole Færgeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ole Færgeman more than expected).
Fields of papers citing papers by Ole Færgeman
This network shows the impact of papers produced by Ole Færgeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ole Færgeman. The network helps show where Ole Færgeman may publish in the future.
Co-authors
The 25 scholars most cited alongside Ole Færgeman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 200 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Hit paper breakdown → | 1994 | 7405 |
| 2 | Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Hit paper breakdown → | 1997 | 1297 |
| 3 | Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention1European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network.1,2Published simultaneously in the European Heart Journal 1998;19:1434–1503 and the Journal of Hypertension (Summary only) 1998;16(10).2 Hit paper breakdown → | 1998 | 1064 |
| 4 | EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE Hit paper breakdown → | 2005 | 1052 |
| 5 | Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S) Hit paper breakdown → | 1998 | 509 |
| 6 | From Vulnerable Plaque to Vulnerable Patient—Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report Hit paper breakdown → | 2006 | 497 |
| 7 | Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial Hit paper breakdown → | 2008 | 476 |
| 8 | 2004 | 460 | |
| 9 | 1997 | 413 | |
| 10 | 2003 | 399 | |
| 11 | 2006 | 389 | |
| 12 | 2003 | 371 | |
| 13 | 2008 | 320 | |
| 14 | 1997 | 319 | |
| 15 | 1975 | 306 | |
| 16 | 2004 | 288 | |
| 17 | 1992 | 286 | |
| 18 | 2004 | 276 | |
| 19 | 2000 | 240 | |
| 20 | 2003 | 236 |
About Ole Færgeman
Ole Færgeman is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine, Cancer Research and Public Health, Environmental and Occupational Health, having authored 200 papers that have together received 21.0k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (102 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (23 papers), Cancer, Lipids, and Metabolism (23 papers), Lipid metabolism and disorders (10 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers), Atherosclerosis and Cardiovascular Diseases (10 papers), Nutritional Studies and Diet (9 papers) and RNA Research and Splicing (9 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (5.3k citations), Cardiology and Cardiovascular Medicine (5.0k citations), Surgery (9.7k citations), Cancer Research (2.0k citations) and Family Practice (137 citations). Ole Færgeman has collaborated with scholars based in Denmark, United States and United Kingdom. Frequent co-authors include Kalevi Pyörälà, ANDERS G. OLSSON, JOHN K. KJEKSHUS, Lars Wilhelmsen, Katherine Margaret Berg, Christian M. Spaulding, Jim Slattery, Michael Gnant, John J.V. McMurray and T.R. Pedersen. Their work appears in journals such as Atherosclerosis, Clinical Genetics, The American Journal of Cardiology, Human Mutation and Circulation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.